SPS
LRMR icon

Susquehanna Portfolio Strategies’s Larimar Therapeutics LRMR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
+165,156
New +$656K 0.01% 665

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Susquehanna Portfolio Strategies's LRMR Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 165,156 shares worth $504K. The stake represents 0.01% of the portfolio and ranks #665 among its holdings.

163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Susquehanna Portfolio Strategies held 165,156 shares of Larimar Therapeutics worth $504K as of Q2 2026.
  • Larimar Therapeutics was a new Susquehanna Portfolio Strategies position in Q2 2026.
  • Larimar Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #665 holding.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.